LEX Diagnostics developed rapid thermal cycling technology which now forms the core of an ultra-rapid molecular diagnostics system. Designed for CLIA waived environments the first LEX Test will detect and differentiate the presence of Influenza A, Influenza B and SARS-CoV-2 virus from nasal specimens in as little as 5 minutes. The direct-from-swab workflow relies upon highly inhibitor-tolerant reagent systems that have been optimised for speed, sensitivity and stability in storage. LEX will present performance data from clinical specimens, ahead of clinical studies ongoing for FDA approval in 2025.
